Africa and Middle East Cardiovascular Epidemiological Study (ACE)
17. februar 2021 oppdatert av: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Prevalence of Cardiovascular Risk Factors in Patients Attending General Practice Clinics in Selected Countries in the Africa and The Middle East Region
This is a cross-sectional, epidemiological study to determine the prevalence of cardiovascular risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension in patients attending General Practice clinics in the Africa and Middle East region.
A total of 4300 patients will be evaluated.
In patients who are found to have previously been diagnosed with cardiovascular (CV) risk factors such as dyslipidemia or hypertension, the level of control of their respective conditions will also be evaluated.
Studieoversikt
Status
Fullført
Forhold
Detaljert beskrivelse
This is a cross-sectional, epidemiological study. In the course of this study, 4,300 persons from general practice, and other non specialist clinics of selected countries of the Africa and Middle East region, will be evaluated for the presence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension. The degree of control of hypertension and dyslipidaemia in those previously diagnosed with these conditions will also be assessed. All medications used for CV risk factor control will also be ascertained.
Patient evaluation will be done by physicians in charge of the selected clinics (who will be trained for case report forms completion) over one visit, through history taking, clinical examination as well as laboratory investigations. Every fifth patient seen on a particular day, fulfilling the inclusion and exclusion criteria would be included in the study.
Studietype
Observasjonsmessig
Registrering (Faktiske)
4386
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Alger, Algerie, 16015
- Pfizer Investigational Site
-
Bejaja, Algerie, 6000
- Pfizer Investigational Site
-
Djelfa, Algerie, 17000
- Pfizer Investigational Site
-
Laghouat, Algerie
- Pfizer Investigational Site
-
M'Sila, Algerie
- Pfizer Investigational Site
-
Relizane, Algerie, 48000
- Pfizer Investigational Site
-
Saida, Algerie, 20000
- Pfizer Investigational Site
-
Tebessa, Algerie
- Pfizer Investigational Site
-
Tlemcen, Algerie, 13000
- Pfizer Investigational Site
-
-
-
-
-
Abu Dhabi, De forente arabiske emirater
- Pfizer Investigational Site
-
Al Ain, De forente arabiske emirater
- Pfizer Investigational Site
-
Dubai, De forente arabiske emirater
- Pfizer Investigational Site
-
Ras Al Khaima, De forente arabiske emirater
- Pfizer Investigational Site
-
-
-
-
-
Alexandria, Egypt
- Pfizer Investigational Site
-
Cairo, Egypt
- Pfizer Investigational Site
-
Shiben Al Kom, Egypt
- Pfizer Investigational Site
-
Tanta, Egypt
- Pfizer Investigational Site
-
-
-
-
-
Accra, Ghana
- Pfizer Investigational Site
-
Jachie-Ashanti, Ghana
- Pfizer Investigational Site
-
Kumasi, Ghana
- Pfizer Investigational Site
-
Sogakope V/R, Ghana
- Pfizer Investigational Site
-
Takoradi, Ghana
- Pfizer Investigational Site
-
-
-
-
-
Amman, Jordan
- Pfizer Investigational Site
-
Irbid, Jordan
- Pfizer Investigational Site
-
Salt, Jordan
- Pfizer Investigational Site
-
-
-
-
-
Bafoussam, Kamerun
- Pfizer Investigational Site
-
Mbandjock, Kamerun
- Pfizer Investigational Site
-
Njombe, Kamerun
- Pfizer Investigational Site
-
Soa, Kamerun
- Pfizer Investigational Site
-
-
Cite Verte
-
Yaounde, Cite Verte, Kamerun
- Pfizer Investigational Site
-
-
Deido
-
Douala, Deido, Kamerun
- Pfizer Investigational Site
-
-
-
-
-
Chongoria, Kenya, 60401
- Pfizer Investigational Site
-
Nairobi, Kenya, 00508
- Pfizer Investigational Site
-
-
-
-
-
Adailiya, Kuwait
- Pfizer Investigational Site
-
Fahaheel, Kuwait
- Pfizer Investigational Site
-
Kuwait, Kuwait
- Pfizer Investigational Site
-
Mishref, Kuwait
- Pfizer Investigational Site
-
Qadesya, Kuwait
- Pfizer Investigational Site
-
Yarmouk, Kuwait
- Pfizer Investigational Site
-
-
-
-
-
Beirut, Libanon
- Pfizer Investigational Site
-
Jbeil, Lebanon, Libanon
- Pfizer Investigational Site
-
Jounieh, Libanon
- Pfizer Investigational Site
-
Tripoli, Libanon
- Pfizer Investigational Site
-
-
-
-
-
Abuja, FCT, Nigeria
- Pfizer Investigational Site
-
Abuja, Garki, Nigeria
- Pfizer Investigational Site
-
Calabar, Nigeria
- Pfizer Investigational Site
-
Enugu, Nigeria
- Pfizer Investigational Site
-
Keffi, Nassarawa, Nigeria
- Pfizer Investigational Site
-
-
-
-
-
Dammam, Saudi-Arabia
- Pfizer Investigational Site
-
Jeddah, Saudi-Arabia
- Pfizer Investigational Site
-
Jeddah 21573, Saudi-Arabia
- Pfizer Investigational Site
-
Makkah, Saudi-Arabia
- Pfizer Investigational Site
-
Riyadh, Saudi-Arabia
- Pfizer Investigational Site
-
Riyadh, Saudi-Arabia, 11584
- Pfizer Investigational Site
-
Yanbu, Saudi-Arabia
- Pfizer Investigational Site
-
-
-
-
-
Kebemer, Senegal
- Pfizer Investigational Site
-
Kedoungou, Senegal
- Pfizer Investigational Site
-
Saint Louis, Senegal
- Pfizer Investigational Site
-
Ziguinchor, Senegal
- Pfizer Investigational Site
-
-
Nabil Choucair
-
Dakar, Nabil Choucair, Senegal
- Pfizer Investigational Site
-
-
Ouakam
-
Dakar, Ouakam, Senegal
- Pfizer Investigational Site
-
-
-
-
-
Kwa-Zulu Natal, Sør-Afrika, 4091
- Pfizer Investigational Site
-
Rondebosch, Sør-Afrika, 7700
- Pfizer Investigational Site
-
-
Gauteng
-
Halfway House, Gauteng, Sør-Afrika, 1685
- Pfizer Investigational Site
-
-
Kwazulu-natal
-
Sydenham, Durban, Kwazulu-natal, Sør-Afrika, 4091
- Pfizer Investigational Site
-
-
Limpopo
-
Mokopane, Limpopo, Sør-Afrika, 0600
- Pfizer Investigational Site
-
Sheshego, Limpopo, Sør-Afrika, 0742
- Pfizer Investigational Site
-
-
Pretoria
-
Mamelodi East, Pretoria, Sør-Afrika, 0122
- Pfizer Investigational Site
-
-
-
-
-
Ariana, Tunisia, 2073
- Pfizer Investigational Site
-
Bouficha, Tunisia, 4010
- Pfizer Investigational Site
-
Messaadine, Tunisia, 4013
- Pfizer Investigational Site
-
Sfax, Tunisia, 3013
- Pfizer Investigational Site
-
Tunis, Tunisia, 1000
- Pfizer Investigational Site
-
Zaghouan, Tunisia, 1100
- Pfizer Investigational Site
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Sannsynlighetsprøve
Studiepopulasjon
Subject selection would be from clinics in a primary care setting
Beskrivelse
Inclusion Criteria:
- Adult aged 18 or above
Exclusion Criteria:
- Pregnant women and/or lactating mothers
- Subjects presenting with any life threatening disease/condition
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension
Tidsramme: At the time of the first visit
|
At the time of the first visit
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Compare the prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the urban and rural population.
Tidsramme: At the time of the first visit
|
At the time of the first visit
|
|
Compare the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the male and female population.
Tidsramme: At the time of the first visit
|
At the time of the first visit
|
|
Stratifying the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension by age groups.
Tidsramme: At the time of the first visit
|
At the time of the first visit
|
|
Ascertain the level of blood pressure and lipids' control as per the European Society of Cardiology (ESC) guidelines in patients who have been previously diagnosed as hypertensive or dyslipidaemic.
Tidsramme: At the time of the first visit
|
At the time of the first visit
|
|
Ascertain the most commonly used medications in those that have been previously diagnosed as diabetic, hypertensive or dyslipidaemic.
Tidsramme: At the time of the first visit
|
At the time of the first visit
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Generelle publikasjoner
- Hamoui O, Omar MI, Raal FJ, Rashed W, Kane A, Alami M, Abreu P, Mashhoud W, Alsheikh-Ali AA. Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. BMC Cardiovasc Disord. 2019 Mar 15;19(1):61. doi: 10.1186/s12872-019-1034-2.
- Brouri M, Ouadahi N, Nibouche D, Benabbas Y, El Hassar M, Bouraoui S, Abad N, Abreu PC, Ikardouchene L. [Cardiovascular risk factors in Algeria. Analysis of the subgroup from the "Africa/Middle East Cardiovascular Epidemiological" Study]. Ann Cardiol Angeiol (Paris). 2018 Apr;67(2):61-66. doi: 10.1016/j.ancard.2018.01.003. Epub 2018 Mar 9. French.
- Raal FJ, Alsheikh-Ali AA, Omar MI, Rashed W, Hamoui O, Kane A, Alami M, Abreu P, Mashhoud WM. Cardiovascular risk factor burden in Africa and the Middle East across country income categories: a post hoc analysis of the cross-sectional Africa Middle East Cardiovascular Epidemiological (ACE) study. Arch Public Health. 2018 Feb 12;76:15. doi: 10.1186/s13690-018-0257-5. eCollection 2018.
- Ahmed AM, Hersi A, Mashhoud W, Arafah MR, Abreu PC, Al Rowaily MA, Al-Mallah MH. Cardiovascular risk factors burden in Saudi Arabia: The Africa Middle East Cardiovascular Epidemiological (ACE) study. J Saudi Heart Assoc. 2017 Oct;29(4):235-243. doi: 10.1016/j.jsha.2017.03.004. Epub 2017 Mar 14.
Hjelpsomme linker
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. juli 2011
Primær fullføring (Faktiske)
1. april 2012
Studiet fullført (Faktiske)
1. april 2012
Datoer for studieregistrering
Først innsendt
12. november 2010
Først innsendt som oppfylte QC-kriteriene
16. november 2010
Først lagt ut (Anslag)
18. november 2010
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
18. februar 2021
Siste oppdatering sendt inn som oppfylte QC-kriteriene
17. februar 2021
Sist bekreftet
1. februar 2021
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- A2581186
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .